Phenotypic and molecular characterization of a Colombian family with phenylketonuria

Nancy Gélvez, Johana Acosta, Greizy López, Derly Castro, Juan Carlos Prieto, Martha Bermúdez, Marta L. Tamayo, .

DOI: https://doi.org/10.7705/biomedica.v36i3.2639
Keywords: Phenylketonurias, phenylalanine hydroxylase, intellectual disability, mutation, genetics, early diagnosis, diet
Abstract Authors Downloads References How to Cite

Abstract

Introduction: Phenylketonuria is a metabolic disorder characterized by severe neurological involvement and behavioral disorder, whose early diagnosis enables an effective treatment to avoid disease sequelae, thus changing the prognosis. Objective: To characterize a family with phenylketonuria in Colombia at clinical, biochemical and molecular levels. Materials and methods: The population consisted of seven individuals of a consanguineous family with four children with suggestive symptoms of phenylketonuria. After signing an informed consent, blood and urine samples were taken for colorimetric tests and high performance liquid and thin layer chromatographies. DNA extraction and sequencing of the 13 exons of the PAH gene were performed in all subjects. We designed primers for each exon with the Primer 3 software using automatic sequencing equipment Abiprism 3100 Avant. Sequences were analyzed using the SeqScape, v2.0, software. Results: We described the clinical and molecular characteristics of a Colombian family with phenylketonuria and confirmed the presence of the mutation c.398_401delATCA. We established a genotype-phenotype correlation, highlighting the interesting clinical variability found among the affected patients despite having the same mutation in all of them. Conclusions: Early recognition of this disease is very important to prevent its neurological and psychological sequelae, given that patients reach old age without diagnosis or proper management.

Downloads

Download data is not yet available.
  • Nancy Gélvez Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia

     

     

  • Johana Acosta Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • Greizy López Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • Derly Castro Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • Juan Carlos Prieto Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • Martha Bermúdez Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • Marta L. Tamayo Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia

References

Vilarinho L, Queirós A, Leandro P, Tavares de Almeida I, Rivera I. Fenilcetonuria revisitada. Arq Med. 2006;20: 161-72.

Santos LL, Fonseca CG, Starling AL, Januario JN, Aguiar MJ, Peixoto MG, et al. Variations in genotype-phenotype correlations in phenylketonuria patients. Genet Mol Res. 2010;9:1-8. http://dx.doi.org/10.4238/vol9-1gmr670

Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat. 2007;28:831-45. http://dx.doi.org/10.1002/humu.20526

Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular bases of inherited disease. Eighth edition. New York: McGraw Hill; 2001. p. 1667-724.

Fernandes J, Saudubray JM, van den Berghe G, Walter JH. Inborn metabolic diseases, diagnosis and treatment. Fourth edition. Würzbur, Germany: Springer; 2006. p. 226-31.

Berry SA, Brown C, Grant M, Greene CL, Jurecki E, Koch J, et al. Newborn screening 50 years later: Access issues faced by adults with PKU. Genet Med. 2013;15:591-9. http://dx.doi.org/10.1038/gim.2013.10

Hagedorn TS, van Berkel P, Hammerschmidt G, Lhotakova M, Saludes RP. Requirements for a minimum standard of care for phenylketonuria: The patients’ perspective. Orphanet J Rare Dis. 2013;8:191. http://dx.doi.org/10.1186/1750-1172-8-191

de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ. Pathogenesis of cognitive dysfunction in phenylketonuria: Review of hypotheses. Mol Genet Metab. 2010;99(Suppl.1):S86-9. http://dx.doi.org/10.1016/j.ymgme.2009.10.016

Scriver CR, Prevost L, Hurtubise M, Konecki D, Dobrowolski SF. Phenylalanine Hydroxylase Locus Knowl-edgebase. 2002. Fecha de consulta: 3 de diciembre de 2014. Disponible en: http://www.pahdb.mcgill.ca/cgi-bin/pahdb/mutation_statistics-1.cgi.

Desviat LR, Pérez B, De Lucca M, Cornejo V, Schmidt B, Ugarte M. Evidence in Latin America of recurrence of V388M, a phenylketonuria mutation with high in vitro residual activity. Am J Hum Genet. 1995;57:337-42.

Santos LL, Magalhaes M de C, Reis Ade O, Starling AL, Januario JN, Fonseca CG, et al. Frequencies of phenylalanine hydroxylase mutations I65T, R252W, R261Q, R261X, IVS10nt11, V388M, R408W, Y414C, and IVS12nt1 in Minas Gerais, Brazil. Genet Mol Res. 2006;5:16-23.

Acosta AX, Silva WA Jr, Carvalho TM, Zago MA. Ten novel mutations in the phenylalanine hydroxylase gene (PAH) observed in Brazilian patients with phenylketonuria. Hum Mutat. 2001;17:77. http://dx.doi.org/10.1002/1098-1004(2001)17:1<77::AID-HUMU19>3.0.CO;2-S

Cazzorla C, Cegolon L, Burlina AP, Celato A, Massa P, Giordano L, et al. Quality of Life (QoL) assessment in a cohort of patients with phenylketonuria. BMC Public Health. 2014;14:1243. http://dx.doi.org/10.1186/1471-2458-14-1243

Guldberg P, Levy HL, Hanley WB, Koch R, Matalon R, Rouse BM, et al. Phenylalanine hydroxylase gene mutations in the United States: Report from the Maternal PKU Collaborative Study. Am J Hum Genet. 1996;59:84-94.

Scriver CR. Why mutation analysis does not always predict clinical consequences: Explanations in the era of genomics. J Pediatr. 2002;140:502-6. http://dx.doi.org/10.1067/mpd. 2002.124316

Scriver CR, Waters PJ. Monogenic traits are not simple: Lessons from phenylketonuria. Trends Genet. 1999;15:267-72. http://dx.doi.org/10.1016/S0168-9525(99)01761-8

Möller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab. 1998;18:1184-91. http://dx.doi.org/10.1097/00004647-199811000-00004

Møller LB, Paulsen M, Koch R, Moats R, Guldberg P, Güttler F. Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab. 2005;86(Suppl.1):S119-23. http://dx.doi.org/10.1016/j. ymgme.2005.07.031

Langenbeck U, Burgard P, Wendel U, Lindner M, Zschocke J. Metabolic phenotypes of phenylketonuria. Kinetic and molecular evaluation of the Blaskovics protein loading test. J Inherit Metab Dis. 2009;32:506-13. http://dx.doi.org/10.1007/s10545-009-1152-6

Viau KS, Wengreen HJ, Ernst SL, Cantor NL, Furtado LV, Longo N. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J Inherit Metab Dis. 2011;34:963-71. http://dx.doi.org/10.1007/s10545-011-9329-1

Sarkissian CN, Gámez A, Scriver CR. What we know that could influence future treatment of phenylketonuria. J Inherit Metab Dis. 2009;32:3-9. http://dx.doi.org/10.1007/s10545-008-0917-7

van Spronsen FJ, Hoeksma M, Reijngoud DJ. Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause? J Inherit Metab Dis. 2009;32:46-51. http://dx.doi.org/10.1007/s10545-008-0946-2

How to Cite
1.
Gélvez N, Acosta J, López G, Castro D, Prieto JC, Bermúdez M, et al. Phenotypic and molecular characterization of a Colombian family with phenylketonuria. biomedica [Internet]. 2016 Sep. 1 [cited 2024 May 19];36(3):390-6. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/2639

Some similar items:

Published
2016-09-01
Issue
Vol. 36 No. 3 (2016)
Section
Original articles

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Crossref Cited-by logo
QR Code